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Background: There is an on-going debate about whether to perform surgery on early stage localised prostate
cancer and risk the common long term side effects such as urinary incontinence and erectile dysfunction. Alternatively
these patients could be closely monitored and treated only in case of disease progression (active surveillance). The aim
of this paper is to develop a decision-analytic model comparing the cost-utility of active surveillance (AS) and radical
prostatectomy (PE) for a cohort of 65 year old men with newly diagnosed low risk prostate cancer.
Methods: A Markov model comparing PE and AS over a lifetime horizon was programmed in TreeAge from a German
societal perspective. Comparative disease specific mortality was obtained from the Scandinavian Prostate Cancer Group
trial. Direct costs were identified via national treatment guidelines and expert interviews covering in-patient, out-patient,
medication, aids and remedies as well as out of pocket payments. Utility values were used as factor weights for age
specific quality of life values of the German population. Uncertainty was assessed deterministically and probabilistically.
Results: With quality adjustment, AS was the dominant strategy compared with initial treatment. In the base case,
it was associated with an additional 0.04 quality adjusted life years (7.60 QALYs vs. 7.56 QALYs) and a cost reduction
of €6,883 per patient (2011 prices). Considering only life-years gained, PE was more effective with an incremental
cost-effectiveness ratio of €96,420/life year gained. Sensitivity analysis showed that the probability of developing
metastases under AS and utility weights under AS are a major sources of uncertainty. A Monte Carlo simulation
revealed that AS was more likely to be cost-effective even under very high willingness to pay thresholds.
Conclusion: AS is likely to be a cost-saving treatment strategy for some patients with early stage localised prostate
cancer. However, cost-effectiveness is dependent on patients’ valuation of health states. Better predictability of
tumour progression and modified reimbursement practice would support widespread use of AS in the context
of the German health care system. More research is necessary in order to reliably quantify the health benefits
compared with initial treatment and account for patient preferences.
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Prostate cancer (PC) – ICD code C.61 ‘Malignant neo-
plasm of the prostate’ following ICD-10-GM classifica-
tion – is the second most frequent cancer among males
in economically developed countries and the most com-
mon cancer in Germany, accounting for 14% and 25% of
total new cancer cases respectively [1]. Since 1990, the
number of new cases has risen by over 50%, amounting
to more than 80,000 new diagnoses in Germany in 2010
[2]. The increase in PC incidence has been related to im-
proved means of early diagnosis, especially through
prostate-specific antigen (PSA) testing [3]. Prostatec-
tomy (PE) is the first line treatment option for early
stage PC. PE is considered the gold standard in urology
because other options such as radiotherapy (RT) cannot
guarantee complete elimination of tumour cells in the
prostate [4,5]. It is also the only treatment for which
there exists favourable high quality clinical evidence
[6,7]. Accordingly, the German Federal Joint Committee
(‘Gemeinsamer Bundesausschuss’, GBA) decided that PE
is the preferred treatment option for early stage PC in
low risk patients because of the lack of prospective, ran-
domised evidence for RT [6].
Because most carcinomas are thought to have a pro-
tracted natural history and more than 85% of patients
are older than 65 years at the time of diagnosis, most pa-
tients die with the disease and not of it [8,9]. This is es-
pecially true for carcinomas that exhibit a low risk
profile, i.e. a low PSA value, no histological conspicuity
suggested by an indicator such as the Gleason score and
confinement to the prostate. For such men, the risk of
over-treatment is associated with negative health im-
pacts resulting from the adverse effects of prostatectomy
[10,11]. Postoperative rates of incontinence (IC) or
erectile dysfunction (ED) of 97% and 72%, respectively,
have been reported within 90 days of PE [12]. Despite
the fact that some patients recover in the long term,
these adverse effects (AE) significantly reduce health re-
lated quality of life [13].
As a consequence, observing strategies have been pro-
posed as an alternative to initial treatment [11,14].
Watchful waiting (WW) is a strategy from the pre-PSA
test era for patients with limited life expectancy. WW
implies no intention to initiate curative treatment. In
case of symptomatic disease progression, only palliative
treatment is offered to patients, and a survival benefit of
primary treatment with PE over WW has been docu-
mented in a prospective, randomised controlled trial
(RCT) [7,15]. Active surveillance (AS), on the other
hand, describes a policy of close monitoring for patients
with a life expectancy >15 years. In cases of disease pro-
gression, curative treatment is triggered.
There exists no evidence from RCTs for AS [16].
Because AS implies close monitoring and curativetreatment when necessary, it can reasonably be assumed
that an AS strategy is more effective in avoiding PC spe-
cific death than WW. In fact, some evidence suggests
that there is no difference in PC death to be expected
between AS and PE [17]. The aim of this article was to
develop a Markov model for the evaluation of AS as an
alternative strategy to PE for the treatment of early stage,
localised prostate cancer in the context of the German
health care system. Owing to the lack of evidence for
AS, we had to base our analysis on reasonable assump-




A decision analytic cost-utility model was developed follow-
ing the standard of the CHEERS checklist, a general guide-
line on decision-analytic modelling [18]. It was performed
from the perspective of the citizens insured by German
Statutory Health Insurance (SHI), which is recommended
by the German Institute for Quality and Efficiency in
Health Care (IQWIG) and includes costs for SHI and out
of pocket payments [19]. The study population consisted of
men newly diagnosed with low risk PC, no other severe
comorbidities and a life expectancy of >15 years. Low
risk PC is characterised by a PSA value ≤10 ng/ml,
Gleason score ≤6 and tumour stage ≤T2a [11].
Men enter the model at the age of 65 years, which
corresponds to the mean age of the cohort in the
underlying clinical study. A Markov model was chosen
to represent this cohort’s course of disease through
different states over time. Quarter-yearly transition cy-
cles were assumed because significant changes in
tumour states could occur after 90 days and long term
adverse effects could be apparent. In order to capture
the full range of costs and effects, we applied a life-
time horizon of 35 years, assuming an age limit of
100 years.
Health outcomes were measured in quality adjusted
life years (QALYs), as quality of life is a central aspect in
the decision whether to treat or not. All costs (€) were
adjusted to 2011 values. Both health outcomes and costs
were discounted by 3%, and the half-cycle correction
was applied. The model was implemented in TreeAge
Pro 2012.
Interventions/model structure
The German Association for Urology has published
guidelines for the treatment of PC that include AS. Ac-
cording to these, AS involves 3-monthly determinations
of PSA value and digital rectal examinations (DRE) in
the first 2 years after diagnosis and bi-annually thereafter
[5]. Additionally, a biopsy should be taken in the first
year and every 3 years after. Treatment can be triggered
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these parameters as well as patient choice. Patients
aged ≤72 years are treated by open radical PE; older pa-
tients receive RT. A recent review revealed no RCTs
comparing the effectiveness of RT and PE with respect
to PC mortality [20]. Conservatively, it was assumed
that RT and PE have the same disease related outcomes.
Downstream treatments such as treatment of adverse
effects, prostate hyperplasia and advanced disease were
assumed not to have an influence on the difference in
mortality between AS and PE. Despite close monitoring,
rapidly growing tumours might progress unnoticed under
AS and develop metastases prior to treatment [21,22].
Complications occurring within 30 days of PE include rec-
tal injury, wound infection, haemorrhage requiring blood
transfusion, deep vein thrombosis and myocardial infarc-
tions [23]. Short term adverse effects such as ED and/or IC
are characterised by occurrence and resolution within
90 days after surgery. Long term adverse effects persist
after 90 days and can be cured only by surgical interven-
tion. In cases of local recurrence after initial PE, RT is theFigure 1 Structure of the model.primary treatment option [5]. As with PE, the adverse ef-
fects of RT can be divided into short term and long term
effects. In addition to IC and ED, bowel problems (BP)
such as abdominal pain, bloating and diarrhoea may de-
velop [24]. Local recurrence is a prerequisite for developing
metastatic disease after initial treatment. Once metastases
have developed, there is no chance of cure and patients will
eventually die of prostate cancer (Figure 1) [25].
Utilities
Baseline utilities
Age-adjusted utility values from the general population
provide a reasonable approximation when condition spe-
cific baseline data are not available [26]. Health state
specific utilities were thus applied as a multiplicative fac-
tor to average, age-adjusted utilities from the German
male population. The latter are based on a representative
study among German citizens (n = 2,049) surveying the
EQ-5D items in the years 2006-2011 [27]. Based on
these data, the functional relationship between mean
EQ-5D utilities and age was estimated with a generalised
Table 1 Utility weights of relevant health states
State Expected SE 95% CI Source
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(Figure 2) [25].value





0.89 0.024 0.91; 0.85 Steward 2005
During PE treatment 0.67 0.041 0.75; 0.59 Steward 2005
During radiotherapy 0.73 0.045 0.82; 0.64 Steward 2005
Post treatment no
adverse effects
0.99 0.05 1; 0.9 Bremner [28],
Liu [33],
own calculation
Post treatment IC 0.83 0.022 0.87; 0.79 Steward 2005
Post treatment ED 0.89 0.013 0.92; 0.86 Steward 2005
Post treatment BP 0.71 0.021 0.75; 0.67 Steward 2005
Post treatment IC, ED 0.79 0.033 0.86; 0.72 Steward 2005
Post treatment IC, BP 0.70 0.036 0.77; 0.63 Steward 2005
Post treatment ED, BP 0.57 0.039 0.65; 0.49 Steward 2005
Post treatment IC, ED, BP 0.45 0.044 0.54; 0.36 Steward 2005
Metastatic disease 0.25 0.015 0.28; 0.22 Steward 2005
AS = Active surveillance.
PE = Prostatectomy.
IC = Incontinence.
ED = Erectile Dysfunction.
BP = Bowel Problems.Health state specific utilities
We identified five studies that reported utility weights
for relevant health states. Two of these presented im-
plausible or inconsistent results because combined ad-
verse effects were valued more highly than single ones
or utility weights >1 were possible, respectively [28,29].
One recent study reported values depending on age and
socio-economic status, which could not be adequately
combined with our baseline utilities [30]. Stewart et al.
provide mean utilities for postoperative health states
from a cohort of 162 men [31]. These values compare
well with the results of Sommers et al. [32]. Stewart
et al. additionally reported utility values for treatment
states and combined adverse events, such as ED and IC.
Utility values for combined adverse events were sur-
veyed as separate health states so no combination
method had to be applied. Furthermore, the quality of
life effects of conservative, i.e. non-surgical, downstream
treatments such as incontinence pads were already in-
corporated in the description of health states. We there-
fore decided to use their preference-based set of utilities
elicited by the standard gamble method. Following Liu
et al. and the results of the meta-analysis by Bremner
et al., we assumed that life under AS has the same utility
as life after treatment without side effects [28,33]
(Table 1).Figure 2 Age adjusted baseline utility German population.Costs
Following the perspective of citizens insured by German
SHI, all direct medical costs incurred by the SHI as well
as by individual patients were included [19]. Indirect
costs were neglected as the study population has passed
retirement age. Equally, post hospital rehabilitation was
not considered as it is typically covered by pension funds.
Resource usage was identified and quantified through lit-
erature research and treatment recommendations from
the Association of German Urologists. Out-patient unit
prices are based on the physician’s fee catalogue 2011
(0.035048 cents/point) [34]. In-patient unit prices are
based on diagnosis related group (DRG) weights from the
German DRG catalogue and the federal base rate for 2011
of €2,963 [35]. For the pricing of pharmaceuticals, we
referred to the German formulary 2011 [36]. Remedies
and other aids were valued according to market prices
investigated using internet research as well as telephone
interviews.
Primary treatments
In the German DRG system, re-hospitalisations within
30 days are coded as one case. Hence, the costs of PE
with and without complications are reflected by the re-
spective DRGs (Table 2). Postoperative monitoring takes
place on an out-patient basis (Table 3). Physicians can
bring to account a maximum of four patient visits per
Table 2 In-patient costs of prostatectomy
In-patient treatment DRG Total costs (€)
Prostatectomy M01B 6,886
Complications M01A 9,526
Table 4 Out-patient costs of active surveillance
Item Quantity p.a. Price/unit (€) Total costs p.a. (€)
AS year 1 2 > 2 1 2 > 2
DRE 4 4 2 Included in lump sum
PSA value 4 4 2 4.80 19.20 19.20 9.60
Biopsy 1 0.33 0.33 18.58 18.58 6.19 6.19
Consultation
fee
4 4 1 1.75 7.01 7.01 1.75
Treatment fee
> 60 yrs
4 4 2 21.20 84.82 84.82 42.41
Insuree lump
sum




0.5 0.16 0.16 16 8.00 2.64 2.64
Sum 174.05 156.33 80.84
DRE = Digital Rectal Examination.
PSA = Prostate Specific Antigen.
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regular biopsies (Table 4). Despite preventive antibiotics,
biopsy may cause urosepsis which requires hospitalization
[37]. Furthermore, symptoms of benign prostate hyperpla-
sia can develop in patients under AS. We assumed that
initially half these patients are treated with alpha-1 ad-
renergic antagonists (Tamsulosin) and the other half
with 5-alpha-reductase inhibitors (Finasteride). Patients
experiencing worsening of symptoms of urinary diffi-
culty require surgical intervention with transurethral
resection of the prostate (TURP) (Table 5). RT is
undertaken by a specialist practitioner. Curative treat-
ment entails two target volumes with a maximum of 72
gray, which is equivalent to 40 times 1.8 gray (Table 6).
Adverse effects
The numbers of general practitioner (GP) and specialist
practitioner (SP) consultations due to diagnosis of erect-
ile dysfunction were derived from a costing study by
Wilson et al. [38]. We estimated consumption of remed-
ies and aids based on the assumption that 70% of pa-
tients would make use of phosphodiesterase (PDE)
inhibitor and 10% of cavernous injections, SKAT/MUSE
or a vacuum pump respectively (Table 7). Symptomatic
treatment of IC is achieved through the use of pads in
the majority of patients (90%). We assumed an equal
distribution of strong, medium and low pads and an
average use of three pads/day. Diapers or permanent
catheters are necessary in 5% of all patients (Table 8).
Costs of managing BP were based on a publication by
Hummel et al. [20].
Metastases
Metastatic stage is characterised by two phases. At first,
cancer is responsive to treatment with luteinizing
hormone-releasing hormone (LHRH) agonists whichTable 3 Out-patient costs of prostatectomy
Item Quantity
p.a.
Price/unit (€) Total costs
p.a. (€)
Follow-up year < 2 2-4 > 4 < 2 2-4 > 4
PSA value 4 2 1 4.8 19.20 9.60 4.80
Consultation fee 4 2 1 1.75 7.00 3.5 1.75
Treatment fee
> 60 yrs
4 2 1 21.20 84.80 42.40 21.20
Insuree lump sum 4 2 1 9.11 36.45 18.22 9.11
PSA = Prostate Specific Antigen.delay progression. Following treatment guidelines, we
assumed a dose of 11.5 mg every 3 months. Eventually,
patients will become refractory and require chemother-
apy. Chemotherapy implies treatment with 142.5 mg of
Docetaxel and 5 mg of Prednisolone every 3 weeks.
Additionally, around 70% of all refractory patients will
develop bone metastases which are treated with zoledro-
nic acid and RT (Table 9) [39]. Radiation therapy as-
sumes a target volume of 35 gray, i.e. 14 times 2.5 gray.
Probabilities
Mortality
No RCTs comparing disease related mortality of PE and
AS could be found in the literature [16]. One American
and one Scandinavian RCT were identified comparing
WW and initial treatment [7,40]. The 10-year results of
the American study (PIVOT) reported overall PC death
of 5.8% and 8.4% in the PE and observation arms re-
spectively [40]. This corresponds to a relative risk (RR)
of 0.69 which is more favourable towards WW than the
results of the Scandinavian Prostate Cancer Group
(SPCG). The difference in results is likely to be because
the PIVOT cohort represented a population with less ad-
vanced disease [40]. However the PIVOT sample also in-
cluded a large number of African Americans (>30%)
who have been shown to suffer from an increased risk of
developing and dying from PC [41,42]. In order to avoid
country specific bias, we chose to use the SPCG data,
which represent the European population more realistic-
ally. The SPCG trial found that PE significantly reduced
the risk of PC death 15 years after diagnosis with a RR =
0.62, 95% confidence interval (CI) 0.44, 0.87. RR over
the time period was estimated by the authors using
Cox proportional hazard models. However, the study
Table 5 Costs other
Item DRG Quantity p.a. Price/unit (€) Total costs p.a. (€)
In-patient treatment
Surgical
Prosthesis* M03C, ZE 58 1 10238.03
Sphincter* M01B, ZE 10 0.5 6393.77 3196.14
Sling* L06A, ZE139 0.5 3677.58 1388.79
Treatment of urosepsis T60E 1 3075.59
TURP M02A 1 3768.93
Out-patient treatment
BPS medication
Finasteride (5 mg, N3) 1.825 139.88 255.28
Tamsulosin (0.4 mg, N3) 1.825 96.43 175.98
*not covered by statutory health insurance (out of pocket).
BPS = Benign prostate syndrome.
TURP = Transurethral resection of the prostate.
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with more advanced disease, i.e. PSA value <50, tumour
stage ≤ T2 and Gleason score ≤10. Furthermore, pa-
tients in the WW group were only treated palliatively
in case of disease progression [43]. Following Pearson
et al. in the base case, we thus assumed that only half
the treatment benefit of PE would be maintained when
compared with AS corresponding to a RR of 0.81. This
also makes our base case results comparable to the
study by Hayes et al. who assume that AS would be
25% more effective than WW, implying a RR of 0.82.
We calibrated the transition probability of developing
metastases prior to treatment under AS on the basis of
the RR of PC mortality after 15 years of 0.81 and the
other model parameters. This was based on the as-
sumptions that the additional risk of PC death under AS
is constituted by silent progression to metastatic disease
and that metastatic PC is a state of terminal illnessTable 6 Out-patient costs of radiotherapy
Item EBM* Quantity
p.a
Price/unit (€) Total costs
p.a. (€)
Consultation fee 25011 1 61.86 61.86
CT Planning 34360 1 38.38 38.38
Radiation plans 25342 2 247.44 247.44
Lump sum/radiation
field
40840 15 140 2100
Radiation 25321 40 35.22 1408.93
>2 fields 25322 40 6.48 259.36
3D-planning 25232 40 9.46 378.52
Sum 4741.92
*EBM = ‘Einheitlicher Bewertungsmaßstab’, i.e. position in the catalogue of
reimbursed out-patient services.[4,22,44]. Background mortality was based on the life table
of the German Federal Statistical Office 2011 [2].
State transition probabilities
We identified a recent systematic review and meta-
analysis of studies comparing the benefits and harms of
AS and PE for the population in question as best avail-
able evidence [45]. If necessary, annual probabilities
were translated into quarter-yearly probabilities via con-
version to rates [46]. Transition probabilities from shortConsultation fee 1436 1 1.75 1.75
Treatment fee > 60 yrs 26212 1 21.20 21.20
Insuree lump sum 1320 1 9.11 9.11
General practitioner
Consultation fee 1436 2 1.75 3.50
Treatment fee > 60 yrs 3112 2 35.75 71.50
Insuree lump sum 3111 2 15.77 31.54
Remedies and aids*
Sildenafil 8.75 44 385
Cavernous injection 2.5 36.62 91.55
(SKAT, MUSE) 2.5 33.19 82.98
Vacuum pump 0.05 301.76 2.66
Ring 4 17 68.00
Sum 768.80
*not covered by statutory health insurance (out of pocket).
Table 8 Costs of managing incontinence
Item Quantity
p.a





Consultation fee 1 1.75 1.75
Treatment fee > 60 yrs 1 21.20 21.20
Insuree lump sum 1 9.11 9.11
General practitioner
Consultation fee 2 1.75 3.50
Treatment fee > 60 yrs 2 35.75 71.50
Insuree lump sum 2 15.77 31.54
Remedies and aids
Pads 983 0.36 350.53
Diapers (20 × 20) 19 0.56 10.3
Net trousers for pads/diapers 0.95 10 9.5
Physiotherapy (Pelvic floor) 12 15 180
Balloon catheter 0.6 21.18 12.7
Bed bag sterile 6.1 2.51 15.3
Leg bag sterile 6.1 4.51 27.4
Sum 744.34
Table 9 Costs of managing metastatic disease




Specialist practitioner 4 See above 128.28
Medication
LHRH Agonist leuprorelin 4 415 1,660
Refractory
Medication
Docetaxel 17.3 1768 30,645.3
Prednisolon 0.87 10.6 9.2
Bone metastases
Out-patient
Radiation 14 See Table 5 1,484.06
In-patient
Bone scan 0.7 1629.65 1,140.76
Medication
Zoledron acid 12 367.98 4,415.76
LHRH = Luteinizing Hormone-Releasing Hormone.
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of the probabilities of long term AE and short term AE,
i.e. P(transition short term to long term AE) = P(AE long
term)/P(AE short term). For transitions to states with
combined AE, statistical independence was presumed
except in the case of IC. Here, it was assumed that 80%
of patients experiencing IC would also experience ED.




Univariate sensitivity analysis was conducted for all
parameters to analyse their isolated impact on cost-
effectiveness. For transition probabilities and utilities,
input values were varied within the 95% confidence
interval. The probability of developing metastases under
AS was varied between assuming no difference in dis-
ease related mortality compared with PE (i.e. RR =1) and
the full treatment effect found in the SPCG trial (i.e. RR
= 0.62). Costs for in-patient treatments were varied by
running the model with DRG rates resulting from max-
imum and minimum days of hospitalisation resulting
from treatment. All other cost variables were tested by
assuming half and double the central estimate. The 10
variables with the highest impact on model uncertainty
are presented in a tornado diagram (Figure 3). Given
that there exists no explicit cost-effectiveness threshold
for Germany, net benefits were calculated with the fre-
quently quoted willingness to pay (WTP) threshold of
€50,000, which was chosen for illustration only to in-
corporate impacts on both effects and costs [49,50].
Based on the tornado analysis, we report threshold
values for variables that changed strategy rankings. Key
assumptions of the model were varied to test the robust-
ness of the base case results. First, we considered alter-
native time horizons of 5, 15 and 30 years. Furthermore,
we tested the influence of applying alternative discount
rates, where both costs and benefits were discounted at
the same rate. Following German recommendations, the
discount rate was varied between using values of 0%, 5%,
7% and 10% [19,51].
Probabilistic analysis
Multivariate probabilistic sensitivity analysis was con-
ducted to assess overall model uncertainty. For this pur-
pose, values were simultaneously and randomly drawn
in second order Monte Carlo simulation. Beta distribu-
tions were adopted for probabilities and utilities and
gamma distributions for costs. The distribution parame-
ters were derived from the model parameter’s expected
value and standard error (Tables 1, 10 and 11). In the
case of costs, the standard error (SE) was calculated
based on the range applied for deterministic sensitivity
Table 10 Transition probabilities
State Event Expected value SE Source*
AS Progression of Gleason Score 0.0263 0.007
Other Progression (DRE/PSA) 0.0268 0.007
Choosing treatment 0.018 0.005
Developing metastatic prostate cancer under active surveillance 0.0023 0.000425 Bill-Axelson [7]; own calculation
Infection due to biopsy 0.02 0.0075 Cambell-Walsh Urology
Develop benign prostate hyperplasia Age dependent Andersson 2004 [48]
Transurethral resection of the prostate due to benign prostate hyperplasia 0.000462 - Andersson 2004; own calculation
Treatment Perioperative death 0.0044 0.00001
Major complication during surgery 0.0472 0.0168
Urethral stricture 0.0344 0.002
Post PE Incontinence and erectile dysfunction short term 0.37 0.0467
Erectile dysfunction short term 0.39 0.0384
Incontinence short term 0.09 0.0113
Keep incontinence and erectile dysfunction long term 0.27 0.0338
Keep incontinence long term 0.28 0.035
Keep erectile dysfunction long term 0.89 0.0831
Disease recurrence 0.00875 0.0032
Progression from recurrence to metastatic disease 0.0127 0.0047 Horwitz 2005 [49]
Death due to prostate cancer after development of metastatic
state during hormonal therapy
0.022 0.0225 Alibhai [44]
Post RT Incontinence short term 0.3 0.0835
Bowel problems short term 0.18 0.0506
Bowel problems and incontinence short term 0.054 0.0068
Keep incontinence long term 0.16 0.02
Keep bowel problems long term 0.152 0.019
Erectile dysfunction long term 0.064 0.016
Keep incontinence and bowel problems long term 0.148 0.0148
IC Sphincter/sling surgery 0.05 0.0075
ED Prosthesis surgery 0.02 0.0003
Death Death due to other reasons Age dependent -
*If not stated otherwise: [45].
AS = Active Surveillance, ED = Erectile Dysfunction.
DRE = Digital Rectal Examination, IC = Incontinence.
PSA = Prostate Specific Antigen.
PE = Prostatectomy.
RT = Radiotherapy.
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probabilistic sensitivity analysis was based on 1,000 rep-
lications, and the results are presented as a cost-
effectiveness acceptability curve (CEAC) and as a scatter
plot on the cost-effectiveness plane.
Validation
For the sake of cross validation a structured literature
search was performed in the databases PubMed, NHS
Centre for Reviews and Dissemination as well as Google
Scholar to compare our results with existing economiccost-utility models of AS and PE. First we looked for
existing reviews of economic evaluations using the
(Mesh-) terms ‘review’, ‘prostatic neoplasm’ and ‘econom-
ics’. After screening titles and abstracts for the terms
‘model’, ‘evaluation’, ‘cost(s) ’, ‘utility’, ‘quality of life’, ‘effect-
iveness’ and ‘benefit’ we analysed full texts. In a second
step we searched for economic evaluations using the
(Mesh-) terms ‘prostatic neoplasm’ and ‘economics’. Face
validity of the model structure and major model assump-
tions was undertaken within our modelling team (FK, BS)
and with our clinical expert (RW). Furthermore, we
Figure 3 Tornado diagram (Net Benefits in €).
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American PIVOT trial for the purpose of external
validation.Results
Base case
Expected, discounted life expectancy was 12.07 years






Conservative treatment of incontinence 186 23.25
Conservative treatment of erectile dysfunction 192 24.03
Radiotherapy 4,742 592.75
Treatment of metastases 447 55.88
Surgical treatment of urosepsis 3,796 384.50
Treatment prostate hyperplasia 108 13.50
Transurethral resection of the prostate 3,769 86.25
Surgical treatment of incontinence 2,292 286.50
Surgical treatment of erectile dysfunction 10,238 1,279.75
Treatment of refractory metastases 7,663.75 957.97
Treatment of bone metastases 1,760.25 220.03
*Quarter yearly except for surgical procedures.adjusted for quality of life. This was associated with dis-
counted costs of €16,468 for PE and €9,585 for AS.
Treatment with PE therefore generated an additional
0.08 life years and caused additional costs of €6,883, cor-
responding to an incremental cost-effectiveness ratio
(ICER) of €96,420 /life year gained. Some 48% or €7,935
of overall costs were caused by initial treatment in the
PE arm. Treatment costs resulting from PE or RT
amounted to €3,463 in the AS arm, accounting for 36%
of all costs. Costs for AS only amounted to €2,178, mak-
ing up 22% of total costs. After adjusting for quality of
life, effects decreased to 7.60 QALYs under AS and 7.56
QALYs with initial surgery. So AS dominated initial
treatment, causing higher effects (+0.04) and lower costs
(−€6,883) in the base case. The lifetime risk of PC death
was 11.49% under AS and 10.92% in the PE cohort.
Sensitivity analysis
AS dominated initial surgery in all time perspectives. Be-
cause the average health of the population as well as the
share of people under AS decreases over time, the bene-
fit of avoiding postoperative AE is most influential in the
first years after diagnosis. As the share of people under
AS decreases and PC mortality increases, this effect is
temporarily compensated for between years 3 and 15.
After this, rapidly increasing other cause mortality limits
the relative influence of additional PC mortality, which
correspondingly puts more weight on patients still under
AS. With increasing values for the discount rate, the
Table 12 Results of sensitivity analysis
Parameter Value Costs (€) Effects (QALY) ICER (€/QALY)
PE AS Difference PE AS Difference
Base case Time horizon 5 11,355 4,080 −7,275 2.971 3.019 −0.048 Dominated
Time horizon 15 15,011 8,263 −6,748 6.454 6.467 −0.013 Dominated
Time horizon 30 16,444 9,564 −6,880 7.545 7.567 −0.022 Dominated
Discount rate 0% 19,013 12,201 −6,811 9.778 9.800 −0.022 Dominated
5% 15,291 8,346 −6,945 6.525 6.549 −0.025 Dominated
7% 14,386 7,376 −7,010 5.713 5.739 −0.027 Dominated
10% 13,376 6,270 −7,106 4.794 4.824 −0.029 Dominated
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AS remained the dominant strategy for all discount rates
between 0% and 10% (Table 12). Figure 3 depicts the re-
sults of the univariate sensitivity analyses in the form of
a tornado diagram that displays the effect of the uncer-
tainty associated with individual parameter values on the
net monetary benefits of AS for a WTP of €50,000. The
utility weight for patients under AS and the probability
of developing metastases under AS have the highest im-
pact on model results. Probabilities of recurrence after
PE and developing metastases as well as the utility
weight for no AE after PE are almost equally influential
variables. Threshold analysis revealed that seven of the
most influential variables changed the strategy ranking
when varied within their 95% confidence intervals
(Table 13). The probability of developing metastases
under AS proved to be particularly influential. The strat-





Probability of developing metastases under AS 0.0023 0.0025
Probability of PC recurrence after PE 0.00875 0.00772
Utility value after PE with no adverse effects 0.99 1
Utility value under AS 0.99 0.98
Probability of developing metastases after
recurrence
0.0127 0.0113
Utility value after PE with ED 0.89 0.91
Costs of treatment of ED 768.8 None
Probability of short term ED 0.77 0.73
Probability of long term ED 0.89 0.79
Probability of long term ED and IC 0.27 None
Probability of short term IC 0.47 None
AS = Active Surveillance.
PC = Prostate Cancer.
PE = Prostatectomy.
IC = Incontinence.
ED = Erectile Dysfunction.corresponding to a RR of prostate cancer death of 0.76.
Additionally we performed a threshold analysis for the
proportion of patients under AS crossing over to cura-
tive treatment. This proportion is driven by the probabil-
ity of disease progressing for any reason (i.e. Gleason
score or DRE + PSA) and men electing treatment with-
out signs of progression. In the base case this corre-
sponds to an annual crossover probability of Pcrossover =
0.071 and 61% of patients under AS being treated. PE
strategy became more effective than AS at a threshold
value of Pcrossover = 0.149 with 81% of AS patients cross-
ing over to radical treatment.Probabilistic sensitivity analysis
Probabilistic analysis resulted in mean discounted costs
of €16,415 (95% CI €13,664, €19,339) for PE and €9,564
(95% CI €8,535, €10,735) for the AS strategy. Mean
QALYs amounted to 7.58 (95% CI 7.06, 7.93) and 7.60
(95% CI 7.07, 7.83) for PE and AS respectively. Figure 4
shows a scatter plot of ICERs for 1,000 repetitions. AS
was the more effective strategy in 56% of all realisations,
and it was always associated with lower costs. Figure 5
shows the corresponding CEAC for AS. Even at very
high WTP thresholds, the probability of AS being the
more effective strategy is more than 50%.Validation
Two decision-analytic models could be identified that
compared the effectiveness of AS and PE for the treat-
ment of early stage prostate cancer in terms of QALYs
generated [29,33], and one other cost-utility study was
found [52]. All these studies were undertaken from an
American perspective. The models published by Hayes
et al. both indicate that more QALYs are generated
under AS than with initial PE (11.07 vs. 10.23 and 8.85
vs. 7.95) [29,52]. The study by Liu et al. reports a smaller
QALY advantage for a comparable cohort of men. In
their study, AS was associated with an additional 0.05
QALYs [33]. The smaller difference in QALYs is likely to
be related to the fact that Hayes et al. assume that utility
Figure 4 Scatter plot.
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Liu et al. assume equal utility in both states. Our study
reports a smaller overall amount of QALYs because the
age related decline in quality of life is also considered.
The only cost-utility study identified also found AS to be
a cost-saving strategy from the perspective of US Medi-
care [52]. This corresponds to a recent study by Keegan
et al. showing that AS is a cost-saving treatment option
when compared with immediate treatment in the con-
text of the US healthcare system [53]. Face validation re-
sulted in model adaptations with respect to development
and treatment of AEs, length of transition cycles as wellFigure 5 Cost-effectiveness acceptability curve for active surveillanceas assumptions concerning resource utilisation. For the
sake of external validation, we ran the model with the
RR of PC death derived from the PIVOT trial. Ceteris
paribus this resulted in the same strategy ranking with
additional 0.01 QALYs gained in the AS arm (7.61).
Discussion
We present the first cost-utility study assessing the cost-
effectiveness of AS and PE in a European context. Our
analysis demonstrated that AS is a cost-saving treatment
strategy for men aged 65 years with low risk, early stage
carcinoma. AS generates more QALYs at lower costs.
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life expectancy was small as other cause mortality
accounted for most deaths and limited the influence of
treatment specific differences of PC death. Sensitivity to
changes in the discount rate and time horizons was low
and did not change strategy rankings.
Despite these results, PE is currently widely applied.
As the calculation of costs shows, this may be because
the current reimbursement rates in Germany set incen-
tives in favour of PE rather than the AS strategy. For ex-
ample, the restricted ambulatory reimbursement for AS
conflicts with the increased patient need for information
and counselling. Also, hospitals cannot charge for pre-
ventive services and patients are not charged co-
payments if they choose the more costly service.
The wide spread of effectiveness results shown in the
scatter plot (Figure 4) illustrates that the results are as-
sociated with considerable uncertainty surrounding key
effectiveness and outcome parameters. Sensitivity ana-
lysis revealed that the results are highly sensitive to vary-
ing the probability of developing metastases under AS.
This reflects the uncertainty concerning the precision of
early stage diagnosis and the associated uncertainty in
comparative effectiveness between AS and PE. The risk
of under-staging, i.e. wrongly diagnosing an aggressive
tumour as low risk, due to the limited predictive power
of current diagnostic tools is a challenge for current uro-
logical research [54]. It has been shown that more than
25% of tumours may be wrongly diagnosed as insignificant
in clinical practice [55,56]. Better diagnostic methods for
identifying particularly aggressive tumours, e.g. by new
molecular markers, analysis of DNA ploidy or CYP3A4
genotype [57], would increase the effectiveness of AS on
account of the reduced number of PC deaths due to under
staging [54].
Given the currently available staging methods, despite
identical clinical parameters, the optimal therapy recom-
mendation may differ depending on the patient’s trade-
off between quantity and quality of life and personal risk
appetite [32]. Some patients may prefer the avoidance of
AEs at the cost of increased risk of dying from PC.
Others might not be willing to carry this risk and, at the
same time, not consider AEs such as ED as a significant
loss of quality of life. For such patients, PE may be a
treatment strategy that is considered comparatively ex-
pensive but still cost-effective by a number of health
care payers. This is highlighted by the fact that, if the
lifetime spent in different health states is not adjusted
for quality of life, PE is associated with an ICER of
€96,420/QALY compared with AS. Also, postoperative
rates of IC and ED - the main drivers of QALY advan-
tage under AS–may differ considerably depending on
the experience of the surgeon and the overall PE volume
of the institution [58,59].Although consideration of individual patient prefer-
ence and local setting is an important issue in clinical
practice, our study aimed to investigate the cost-utility
of AS from a broader health care systems perspective.
One of the strengths of our model is the use of age ad-
justed, population specific utilities in addition to health
state specific utility weights. Although this methodology
has been demanded by health economists, it is hardly
applied in health economic evaluations [60]. Utilities can
have a big influence on model results, and disregarding
the utility level of the general population overestimates
the amount of QALYs generated. Especially in an elderly
study population, the effects of age dependent decline in
mean utility can significantly influence QALY gains.
Our study is the first evaluation that systematically in-
cludes costs for PC management in a European country
in the decision analysis. Prices for health services in
European countries can differ substantially from those in
the US and affect the transferability of results of eco-
nomic evaluations [61]. The costs quoted for the PSA
test in the US evaluation, for example, were almost 80%
higher than in Germany, and the costs for PE were over
20% higher (based on an exchange rate of $0.75/€).
Limitations
A limitation of this study is the restricted quality of evi-
dence concerning disease specific outcomes of treat-
ments. We based our study on the RR of dying from PC
from an RCT comparing WW with PE. WW describes a
different strategy from AS and is more likely to favour
PE as a treatment option. We tried to take account of
this by conservatively assuming only half the treatment
benefit being maintained under AS and performing wide
range sensitivity analysis. We did not include all possible
treatment options in our model. There is no conclusive
comparative evidence available for alternative treatment
options such as brachytherapy or intensity modulated
radiation therapy [20,62]. Finally, we assumed that surgi-
cal treatment of benign prostate syndrome under AS did
not affect the probability of disease progression, which
might not be realistic. However, as a reduction in the
probability of disease progression would favour AS, this
corresponds with our conservative modelling approach.
Conclusion
The model results indicate that the difference in overall
health outcomes between AS and PE is small. On aver-
age, approximately one month of life is gained by having
immediate surgery; when QALYs are considered, about
two additional weeks of life spent in perfect health can
be gained by choosing AS. Given the cost difference, the
cost-utility analysis replaces the clinical ambiguity with a
more solid conclusion that AS may offer better value for
money, given the assumptions and perspective of this
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bursement practise in Germany sets incentives in favour
of PE rather than the AS strategy. This study may serve
as a starting point to analyse the costs and incentives as-
sociated with existing reimbursement patterns in com-
parison with alternative arrangements.
The model results are subject to substantial uncer-
tainty so that they must be handled with caution. This
confirms the importance of ongoing clinical studies,
such as the HAROW study in Germany [63] and the
German RCT PREFERE [64], that will improve the evi-
dence base in future years. The model needs to be up-
dated as soon as new data from these studies are
available. Appropriate staging and risk prediction, which
allows the differentiation of high and low risk tumours,
plays an important role in decisions about the optimal
clinical strategy. Therefore, further research is needed to
allow for a better stratification of invasive interventions
to high risk patients. This cost-utility analysis can be
used for early evaluation of the potential impact of dif-
ferent newly evolving diagnostic strategies on the costs
and effects of PC management to inform further re-
search and development [65].
This study revealed that whether PE is considered ef-
fective depends not only on clinical data but also on pa-
tient preferences about the role of quality of life in
decision making. Existing evaluations are typically based
on estimates of mean utility gains, which are insensitive
to this aspect of benefit. Further research is necessary to
better determine the appropriate role of preferences in
existing evaluation frameworks. Finally, there is a need
for further research on decision aids that make such in-
formation accessible to PC patients. Traditional ap-
proaches to informing the decision have been shown to
understate the importance of postoperative AEs [66].
Ideally, these aspects could be combined so that an ana-
lysis of existing incentives and the integration of infor-
mation from improved biomarker based risk prediction,
valuations of health states and cost-effectiveness would
lead to new models of fully personalised and cost-
effective prostate cancer care.
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